Objective: To investigate the use of peri-implant crevicular fluid (PICF) interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), and matrix metalloproteinase-8 (MMP-8) biomarkers in distinguishing between healthy implants (H), peri-implant mucositis (MU), and peri-implantitis (PI).
cytokines are some of the most investigated biomarkers in periimplant diseases, as they play an important role in cascading inflammatory responses that are cellular and vascular. 13 The presence of polymorphonuclear cells (PMN) and abundance of fibroblast matrix metalloproteinase-8 (MMP-8) had also been shown to be pertinent to the early detection of PI, which usually follows the release of those cytokines. 14, 15 The destruction of connective tissue is a significant determinant of the progression of peri-implant lesions that is essentially driven by MMP-8. This collagenase is known to be the major MMP detected in periodontitis and is thought to be a potential biomarker of PI.
IL-1β, TNF-α, IL-6, and MMP-8 have been investigated in conjunction with bleeding on probing, gingival index, and probing depths, to prevent and profoundly comprehend pathogenesis of peri-implant diseases. 16 Their concentrations also vary markedly in normal biologic, pathogenic conditions as well as after therapeutic interventions. 17 Peri-implant crevicular fluid (PICF), similar to gingival crevicular fluid around teeth, can be an indicator of inflammatory exudates, through which those biomarkers could be collected. PICF is easily accessible, non-invasive, and sequentially determinable; therefore, if variation in cytokine and MMP-8 levels matches severity and classification of diseases in reference to health, routine biomarkers testing could become a personalized diagnostic tool in clinical practice. 11, 18 A published systematic review and meta-analysis, including articles up to 2013, investigated TNF-α and IL-1β in PICF, showing robust levels in disease compared to health, but no significant difference between MU and PI. 19 Nonetheless, the extent of inflammation markedly increases from MU to PI, as shown by the majority of clinical studies. Additionally, IL-6 is one of the most investigated proinflammatory cytokines between healthy and diseased peri-implant tissues. [20] [21] [22] [23] [24] [25] MMP-8 was very useful to monitor the rapid destruction of connective tissue that marks the progression of MU and PI. 18, 26 Hence, this study aimed at (1) investigating the potential use of IL-1β, IL-6, TNF-α, and MMP-8, as biomarkers of implants health, periimplant mucositis, and peri-implantitis conditions in PICF; (2) attempting to develop a recognizable pattern of cytokines and MMP-8 release; and (3) identifying factors that may influence results of previous studies to minimize discrepancies in future investigations.
| MATERIAL AND METHODS
This systematic review and meta-analysis was performed and written following the 27-item PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement (Moher et al 2009). The PRISMA checklist is attached to the appendix of this article (Supporting Information Checklist 1).
| Focus question
The focus question was developed considering the Population, Intervention, Comparison, and Outcome (PICO) elements (Stone 2002) and as follows: Could cytokine and MMP-8 levels in the PICF be used to distinguish between health (H), MU, and PI?
P: Systemically healthy subjects who received dental implants.
I: IL-1β, IL-6, TNF-α, and MMP-8 biomarkers can be used to differentiate between H, MU, and PI.
C: Investigating the presence or absence of a difference in the cytokine and MMP-8 levels between implants with H, MU, and PI.
O: There is a difference in the level of IL-1β, IL-6, TNF-α, and
MMP-8 between (1) H versus MU; (2) H versus PI; and (3) MU
versus PI.
| Search strategy
Electronic and manual literature searches were conducted by two reviewers (IG, ZC) independently, using PubMed/MEDLINE, EMBASE, and Cochrane Library up to March 2018 without language restriction.
For the PubMed library, the search terms were as follows: (dental 
| Data extraction and selection criteria
Data from the eligible studies were extracted by two reviewers (IG, JZ) independently. The inter-reviewer disagreement was resolved by discussion as well as consultation with senior author (HLW). Corresponding authors were contacted in cases of missing or unclear data.
For this systematic review, eligible studies met the following inclusion criteria: (1) original cross-sectional and longitudinal prospective clinical studies with the collection of pro-inflammatory cytokines in PICF from individuals with PI or MU; (2) studies analyzed protein expression by enzyme-linked immunosorbent assay (ELISA) or flow cytometry using a cytometric bead array system. The exclusion criteria comprised of: (1) animal, in vitro studies, case reports, and reviews;
(2) studies with quantification of pro-inflammatory cytokines in tissue biopsies or saliva; (3) only analysis of osteogenic markers; (4) unreported exact numbers of cytokine levels; (5) fluid collection during early osseointegration; (6) unclear peri-implant disease criteria; and (7) unreported anti-inflammatory and antibiotic medication in inclusion criteria.
| Risk of bias assessment
The criteria used to assess the quality of selected studies is the NIH 30 Galbraith plots analyses were conducted to investigate the potential source of heterogeneity among studies. 31 3 | RESULTS
| Study selection
The literature selection process is illustrated by a PRISMA flowchart ( Figure 1 ). Initial screening yielded a total of 291 records, 140 articles FIGURE A1 Galbraith plot assessing heterogeneity of studies included in the comparison of IL-6 (and TNF-α) between H and MU, MU and PI, H and PI 
| Description of the studies
The most studied cytokine was IL-1β (n = 14), followed by IL-6 (n = 8)
and TNF-α (n = 6 Figure 2B ) showed that the considerable heterogeneity was generated by one study. 25 With this study removed, the heterogeneity Figure 2C ). The result demonstrated that the IL-1β in PI site was similar to that in MU site (SMD: 1.52, 95% CI:
−0.03, 3.07; P = .055), with significant heterogeneity among these studies (I 2 = 91.5%, P < .001). The Galbraith plot ( Figure 2D ) also showed that the considerable heterogeneity was generated by one study. 25 The heterogeneity decreased effectively (I 2 = 0.0%, P = .734) upon removal of that study, and the result became significant (SMD:
0.60, 95% CI: 0.12, 1.08; P = .015).
Nine studies 2, 11, 25, 32, 34, 35, 38, 39, 41 reported the difference in IL-1β between H and PI ( Figure 2E ). Meta-analysis of these data showed IL-β release was much higher in PI compared to H sites (SMD: 2.21, 95%
CI: 1.32, 3.11; P < .001). However, high degree of heterogeneity was noted (I 2 = 92.6%, P < .001). The Galbraith plot ( Figure 2F ) demonstrated that the heterogeneity came from three studies. 25, 32, 35 After excluding the data of these studies, the homogeneity test showed moderate heterogeneity among the remaining 12 studies (I 2 = 43.6%, P = .115), and results showed that the SMD was 1.06 (95% CI:
0.71-1.42; P < .001).
| Meta-analysis of IL-6 and TNF-α
When comparing H and MU, four studies 24, 25, 33, 42 reported levels of IL-6 and three studies [23] [24] [25] reported the levels of TNF-α. Statistical differences were found in both cytokines ( Figures 3A and 4A Figure 3B ). PI group showed significantly higher levels of IL-6 than that in MU group (SMD = 1.46; 95% CI: 0.36, 2.55; P = .009). For PI versus H, IL-6 was investigated in five studies 2, 25, 34, 41, 42 ( Figure 3C ) and TNF-αwere reported in four studies 23, 25, 34, 36, 41 ( Figure 4B ). Results showed that PI group has higher releasing level in both IL-6 (SMD: 1.72; 95% CI: 0.56, 2.87; P = .004) and TNF-α (SMD: 3.78; 95% CI: 1.67, 5.89; P < .001). Metaanalyses revealed high heterogeneity between these studies, with I 2 ranged from 80.3% to 98.1%. The Galbraith plot (Appendix Figure A1) did not show any specific papers contributing to heterogeneity.
| MMP-8 results
Only five articles were included in this review investigating MMP-8 in healthy conditions versus peri-implant diseases. marked both high and significant. 15 Further, a combination of Abbreviations: AVBL, average bone loss; BoP, bleeding on probing; CD, cluster differentiation; F, fundus; GI, gingival index; GM-CSF, granulocyte -macrophage colony-stimulating factor; IFN, interferons; IL, interleukin; mGI, modified gingival index; MIP, macrophage inflammatory protein; MMPs, metalloproteinases; MU, mucositis; OPG, osteoprotegrin; PD, pocket depth; PDGF-BB, platelet derived growth factor beta polypeptide; PGE2, prostaglandin E2; PI, peri-implantitis; S, sulcular; TIMP, tissue Inhibitor of metalloproteinases; VEGF, vascular endothelial growth factor. microbiological profiling and MMP-8 found to have increased the accuracy of results previously obtained. 
| Quality and risk assessment
According to NIH Quality Assessment tool, risk assessment of bias was conducted. A study reporting less than 4 (No/NR) was defined with low risk. Any higher scores than 4 increased the bias risk and were concluded to be fair. Ten studies were regarded "good" and 9 were "fair." These were also shown in Table 3 .
| Publication bias
The publication bias was presented by Egger test in Appendix Figure A2 . For IL-1β, there was no evidence of publication bias, according to Egger's test, in the comparison of H to MU sites (P = .159), MU and PI (P = .08). However, publication bias was found While the molecular mechanism is not fully comprehensible, it is illustrated that in the inflammatory stage of wound healing, IL-1β and TNF-α are chiefly responsible for prolonging plasminogen pathway of H and PI. 33, 55 To our knowledge, this is the first meta-analysis investigating IL-6 in H, MU, and PI. IL-6 was found to be more sensitive to severity of inflammation in peri-implant tissues.
Regarding TNF-α, there were insufficient studies to compare its level between MU and PI; therefore, meta-analysis could not be con- In this meta-analysis, a strict inclusion criterion featured clear definitions of H, MU, and PI. Unclear definitions were either lacking a specific definition, involving therapeutic intervention prior to assessment 47, 56 or did not mention bone loss as the distinguishing parameter of MU from PI. 23 In the study of Panagakos, 39 MU was comprised of bone loss to a limit of 30%. MU was stringently defined as the absence of bone loss, so this study was excluded from MU. This criterion leads to a better distinction of disease and thus enables better judgment of biomarkers use.
While many methodological features of analysis were similar in the included studies, the functioning time of implants differed. This is a limitation to relating cytokine levels to the onset of peri-implant diseases. Similarly, publication bias was found in the comparison of IL-1β in H to PI. Results show high heterogeneity I 2 varying from 80.3% to 98.1%, which led to the use of the random effect model. Liu et al depict the highest heterogeneity in evaluation of IL-1β in all three conditions. One reason could be that cytokine levels were associated with high mobility group box 1 (HMGB1) protein increase as the principal investigated variable. 25 In other studies, the main reason for high heterogeneity could be attributed to the nature of studies, that is, the majority of included studies are cross-sectional. Alternatively, longitudinal peri-implant disease monitoring, combined with a non-treatment phase, could recognize a cluster of host response biomarkers associated with breakdown of tissues. 22, 47, 57, 58 Limited evidence exists to show the number of subjects with a sufficient sample size; that is, no calculations of statistical power were 35, 61 Moreover, the type of protein assay used could affect the quality of results based on using different manufacturer products of ELISA and multiplex bead assays. Cytokine multiplex assays were found to be "comparable in sensitivity, accuracy, and reproducibility"
to ELISA for the same analyte. 62 Concentration values followed a similar pattern among ELISA and bead assays but yielded different absolute cytokine concentrations. A trend of varied cytokine levels was expressed in this review. 63 In accordance with Khan's study, a trend is most important to monitor development and progression of disease.
Finally, most studies lacked data on sensitivities and specificities to cytokines and time at which PICF samples were acquired; hence the probability of false positive or false negative results could not be calculated. 
| CONCLUSION

